CROSS COUNTRY HEALTHCARE INC (CCRN)

Services-Help Supply Services · market cap $426M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
RP101	Phase 2	Dry Eye Syndromes
Chloroprocaine HCl 2%	Phase 3	Axillary Nerve Block
Chloroprocaine HCl 1%	Phase 2	Short Duration Lower Limb Surgery Via Spinal Anaesthesia
rhNGF 20 µg/mL	Phase 2	Dry Eye Syndrome
30 mg Paracetamol 3% (1 mL)	Phase 2	Pain, Postoperative
Paracetamol 3%	Phase 2	Phase 1: Pain Management
dimiracetam	Phase 2	Neuropathy
Chloroprocaine 3% eye gel	Phase 3	Local Anesthetic

Price & technical context

3-month

+33.0%

6-month

+44.7%

12-month

+3.7%

52-wk range

$7.53–$14.23

vs 50-day MA

+0.6%

vs 200-day MA

+23.2%

Realized vol

53.8%

Max drawdown

-58.7%

Daily closes through 2026-07-21. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CCRN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.